A 61-Year-Old Man With ALK-Rearranged NSCLC

Video

A 61-Year-Old Man With ALK-Rearranged NSCLC

Case: A 61-Year-Old Man WithALK-Rearranged NSCLC

  • A 61-year-old man presented with recent onset shortness of breath and swelling above left clavicle.
  • Relevant PMH:
    • Nonsmoker, no previous CV- or pulmonary-related complications
  • PE: Lungs, right-sided wheezing on auscultation; left supraclavicular lymphadenopathy, palpable
  • Diagnostic workup:
    • Labs: WNL
    • Lymph node biopsy showed adenocarcinoma
    • CT CAP showed a 2.5-cm solid pulmonary lesion in the left inferior lobe and multiple liver lesions
    • CT‐guided core needle biopsy of the lung lesion revealed lung adenocarcinoma
    • Molecular testing:
      • EGFR, BRAF, KRAS, MET, RET, NTRKwild-type
      • IHC;ALK-rearrangement
      • PD-L1 TPS, 0%
    • Contrast‐enhanced MRI of the head showed multiple brain metastases
  • Treatment:
    • Started on alectinib 600 mg BID; achieved a partial response including regression of CNS disease
    • Patient developed grade 3 myalgia; dose reduced to 450 mg BID, sustained at grade 2
  • Imaging at 9 months showed disease progression in the lung mass and liver; stable CNS disease
    • Lung biopsy, mutation analysis;ALKG1202R
  • He was started on brigatinib 90 mg once daily and tolerated the dose well; after 1 week, her dose was increased to 180 mg once daily (2 90-mg tablets)
    • Partial response with significant shrinkage in lung, liver, and CNS lesions
Related Videos
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Related Content